Key result
GLP-1 receptor agonists linked to lower AF incidence in patients with cardiovascular risk factors.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May support lower AF risk with GLP-1 RAs in CV patients; leaves open confirmation in dedicated prospective trials.
This research did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors. Basem M. Mishriky has served on Advisory Board Panel for AstraZeneca and the consulting fees from AstraZeneca paid to the East Carolina University. Doyle M. Cummings has received research grant support from Novo-Nordisk Pharmaceuticals. The other authors declare that there are no conflict of interests. The peer review history for this article is available at https://publons.com/publon/10.1002/DMRR.3436. The data that support the findings of this study are available from the corresponding author upon reasonable request.
No takes yet. Share an insight, caveat, or question.
Hamedi et al. (2021) studied this question. GLP-1 receptor agonists were found to be associated with a reduced incidence of atrial fibrillation in patients with cardiovascular risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: